51. Scleroderma Clinical trials / Disease details
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01553981 (ClinicalTrials.gov) | March 2012 | 11/3/2012 | A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma | A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma | Lung Diseases, Interstitial | Drug: Tadalafil;Drug: Placebo | Sanjay Gandhi Postgraduate Institute of Medical Sciences | NULL | Completed | 18 Years | 70 Years | Both | 40 | Phase 3 | India |
| 2 | NCT01042158 (ClinicalTrials.gov) | January 2010 | 4/1/2010 | A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis | A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis | Pulmonary Arterial Hypertension;Systemic Sclerosis;Scleroderma Spectrum of Diseases;Connective Tissue Disease;Pulmonary Hypertension | Drug: tadalafil and ambrisentan upfront combination therapy | Johns Hopkins University | National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);Eli Lilly and Company;United Therapeutics;The Cleveland Clinic;University of Texas;Stanford University | Completed | 18 Years | N/A | All | 25 | Phase 4 | United States |
| 3 | NCT01117298 (ClinicalTrials.gov) | November 2009 | 3/5/2010 | A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study | Raynaud's Phenomenon;Digital Ulcers;Scleroderma | Drug: Tadalafil;Drug: Placebo | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Institute of Postgraduate Medical Education and Research;Postgraduate Institute of Medical Education and Research;Army Research and Referral hospital | Completed | 18 Years | 65 Years | Both | 66 | Phase 3 | India |
| 4 | NCT00626665 (ClinicalTrials.gov) | December 2007 | 21/2/2008 | Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | Raynaud Disease | Drug: Tadalafil | Sanjay Gandhi Postgraduate Institute of Medical Sciences | NULL | Completed | 18 Years | 70 Years | Both | 25 | Phase 3 | NULL |